LLY
Eli Lilly and Company
LLY has the edge over PRE overall, supported by lower modeled downside and stronger fundamentals.
PRE
Prenetics Global Limited
PRE's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Weak |
PRE's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRE PE Valuation
PRE has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PRE on earnings quality, reporting a profit while its opponent remains loss making.
PRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.16 | -$0.29 |
| Q1 2026 | -$4.58 | -$0.77 |
| Q4 2025 | -$4.02 | -$0.31 |
| Q3 2025 | -$3.56 | +$0.26 |
| Q2 2025 | -$3.87 | +$0.27 |
| Q1 2025 | -$3.81 | +$1.51 |
| Q4 2024 | -$3.71 | +$1.90 |
| Q3 2024 | -$3.82 | +$0.24 |
PRE is still losing money, but far less than before: $4.16 per share over the past year, against $96.85 at its worst in mid-2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRE on profitability, with a higher operating margin.
PRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $46.5M | +163% |
| Q1 2026 | $36M | +108% |
| Q4 2025 | $36.6M | +249% |
| Q3 2025 | $23.6M | +203% |
| Q2 2025 | $17.7M | +198% |
| Q1 2025 | $17.3M | +170% |
| Q4 2024 | $10.5M | +99% |
| Q3 2024 | $7.8M | +59% |
PRE has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -47% | +9.8 points |
| Q1 2026 | -27% | +34 points |
| Q4 2025 | -34% | +124 points |
| Q3 2025 | -26% | +126 points |
| Q2 2025 | -57% | +122 points |
| Q1 2025 | -61% | +81 points |
| Q4 2024 | -158% | +59 points |
| Q3 2024 | -152% | +114 points |
PRE's operating margin was −47% last quarter, up 9.8 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | -$12.1M | -$12.1M |
| Q4 2025 | -$22M | -$22M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PRE's free cash flow was −$34M over the past year, against $0 the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PRE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +284K shares |
| 1 year | +30% | +4M shares |
| 3 years | +63% | +6.7M shares |
| 5 years | +561% | +14.7M shares |
PRE has 17M diluted shares, up 30% from a year ago, despite $40M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $26.9M |
| Q1 2026 | $13.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PRE spent $40M buying back its own shares over the past year, after none the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 50.8x | High |
| Q1 2021 | 2.2x | Moderate |
| Q4 2020 | 0.5x | Very low |
PRE's net debt is more than 20 years of its operating earnings (EBITDA).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 13.9 | Oversold |
PRE's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRE PE vs Healthcare Sector
PRE has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRE on trend strength, trading above more of its moving averages.
PRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.9 | 12% below |
| 20 week MA | $19.9 | 16% below |
| 50 week MA | $18.8 | 11% below |
| 100 week MA | $13.4 | 24% above |
| 200 week MA | $10.7 | 56% above |
PRE has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 56% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRE on returns for 2026, with the stronger performance.
PRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $120.6 | $31.5 | -74% |
| 2023 | $31.5 | $5.91 | -81% |
| 2024 | $5.91 | $5.70 | -3.6% |
| 2025 | $5.70 | $16.9 | +196% |
| 2026 YTD | $16.9 | $16.7 | -0.9% |
PRE's yearly returns have swung widely, from +196% in 2025 to −81% in 2023. It's down 0.9% so far in 2026.